Purple Biotech Ltd. (PPBT)
NASDAQ: PPBT
· Real-Time Price · USD
0.62
-0.02 (-3.46%)
At close: Oct 16, 2025, 3:59 PM
0.62
-0.26%
After-hours: Oct 16, 2025, 06:06 PM EDT
-3.46% (1D)
Bid | 0.61 |
Market Cap | 8.14K |
Revenue (ttm) | n/a |
Net Income (ttm) | -2.61M |
EPS (ttm) | -48.68 |
PE Ratio (ttm) | -0.01 |
Forward PE | -0.97 |
Analyst | Buy |
Dividends | n/a |
Ask | 0.64 |
Volume | 116,324 |
Avg. Volume (20D) | 1,080,081 |
Open | 0.64 |
Previous Close | 0.64 |
Day's Range | 0.61 - 0.65 |
52-Week Range | 0.53 - 13.95 |
Beta | -0.84 |
Ex-Dividend Date | n/a |
About PPBT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PPBT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PPBT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-45.07%
Purple Biotech shares are trading lower after the ...
Unlock content with
Pro Subscription
1 month ago
+0%
PPBT stock has given up its prior loss. Purple Biotech shares were trading lower. The company announced its second CAPTN-3 trispecific antibody, targeting TROP2 in development.